

Those projects furthest advanced in the cardiovascular disease area are autologous (*ie* derived from a patient’s own tissue) and are delivered via a catheter. A more detailed listing of diseases targeted by stem cell-based therapeutics is provided in Table 2. Phase 3 products for targets other than cardiovascular disease include those for graft versus host disease, Crohn’s disease/inflammatory bowel disease (one allogeneic and one autologous), hematological malignancy and osteonecrosis. The potential of these products is explored further in later chapters in this report.

Figure 8 shows the number of projects in each broad therapeutic area and the stage of development of each of these projects.

